Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Multinacional farmacéutica holandesa busca licenciatarios de sus plataformas de producción de anticuerpos monoclonales humanos en el campo de inmunooncología o enfermedades inmunológicas

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TONL20190603001
Publicado:
25/06/2019
Caducidad:
25/06/2020
Resumen:
Una multinacional farmacéutica holandesa está especializada en desarrollar productos terapéuticos en los campos de inmunooncología y enfermedades inmunológicas mediante el uso de sus plataformas de ratones transgénicos para producir anticuerpos humanos: anticuerpos comunes y de cadena pesada. El estudio de los anticuerpos monoclonales terapéuticos es uno de los segmentos de crecimiento más rápido de la industria farmacéutica mundial. La empresa busca socios en los sectores de inmunooncología y enfermedades inmunológicas para licenciar la plataforma de anticuerpos humanos o colaborar en el desarrollo de productos. La cooperación se establecerá en el marco de un acuerdo de investigación o licencia.

Details

Tittle:
A Dutch multinational pharmaceutical company is looking for licensing partners of its human monoclonal antibody production platforms in the field of immuno-oncology or immunologic diseases.
Summary:
A Dutch multinational pharmaceutical company focusses on therapeutic product development in the fields of immuno-oncology and immunologic diseases, using its proprietary transgenic mouse platforms producing human antibodies: common and heavy-chain only antibodies. The company is looking for partners within immuno-oncology or immunologic diseases to license the human antibody platform to, or for product co-development partnering. A research cooperation agreement or a license agreement is foreseen
Description:
A multinational pharmaceutical biotech company, having premises in Europe-the Netherlands, develops innovative therapies for cancer and immune-driven diseases. The company has a growing clinical portfolio and an emerging pipeline of next generation biologics based on its two patented transgenic mouse platforms for producing fully human antibodies.

Therapeutic monoclonal antibody (mAb) is one of the fastest growing segments of the global pharmaceutical industry. More and more approved mAbs are fully human antibodies. One of the major engines to generate fully human antibodies is genetically engineered mice technology.

The company is building its proprietary pipeline internally, through collaborations with co-development partners, as well as through selected preclinical and clinical stage asset acquisitions. The company also licenses the platforms to companies and academic institutions through its subsidiary.

The company is looking for licensing partners to license-out its human antibody producing transgenic mouse platforms within the field of immuno-oncology or immunologic diseases. For both commercial and academic partners also co-development opportunities and single-target evaluation programs are available based on these antibody platforms. These provide efficient, low risk high value, pharmaceutical compliant means to develop and produce highly advanced mAb therapeutics.

The company is looking preferably for other European product developing entities within immuno-oncology or immunologic diseases to license the human antibody platform to, or for product co-development partnering using the antibody platform. A research cooperation agreement or a license agreement is foreseen.

Advantages and Innovations:
The transgenic mouse platforms yield either i. human common monoclonal antibodies (mAb) or ii. human heavy-chain only mAbs.

i. The common mAbs display:
- normal antibody and affinity maturation in vivo
- intact somatic hypermutation
- pM to nM affinity ranges
- no lead optimization required
- no humanisation step required
- preventing affinity-reduction risks
- timely lean production

These mAbs are used in marketed therapeutics as e.g. checkpoint inhibitors and other applications.

ii. The human heavy-chain only mAbs display:
- high affinity, solubility and stability
- good expression
- non-aggregate in vivo
- no lead optimization required
- no humanisation step required
- preventing affinity-reduction risks
- timely lean production

These mAbs are used for generating e.g. single-domain Abs, bispecific Abs, and chimeric-antigen receptor (CAR) structures like CAR-T or CAR-NK.
Stage of Development:
Already on the market
IPs:
Patents granted,Trade Marks,Exclusive Rights
CommeR Statunts Regarding IPR Status:
Global coverage of the patents.

Partner sought

Type and Role of Partner Sought:
The company is seeking collaboration with other companies (SME´s) and academia related to its expertise:
i. pharmaceutical product developer: in-licensing of the transgenic human mAb platform or co-development.
ii. academic institute: in-licensing of the transgenic human mAb platform or co-development.

Client

Type and Size of Client:
Industry SME 50-249
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
Dutch
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06002009 Diseño molecular
06002007 Ensayos in vitro, experimentos
06001015 Productos farmacéuticos / medicamentos
06001009 Terapia genética - ADN